The World-Wide Randomized Antibiotic Envelope Infection Prevention (WRAP-IT) Trial: Long-Term Follow-Up.

[1]  D. Hodge,et al.  Trends of Cardiovascular Implantable Electronic Device Infection in 3 Decades: A Population-Based Study. , 2019, JACC. Clinical electrophysiology.

[2]  J. Nielsen,et al.  Incidence of device-related infection in 97 750 patients: clinical data from the complete Danish device-cohort (1982–2018) , 2019, European heart journal.

[3]  B. Wilkoff,et al.  Antibacterial Envelope to Prevent Cardiac Implantable Device Infection , 2019, The New England journal of medicine.

[4]  S. Connolly,et al.  Prevention of Arrhythmia Device Infection Trial: The PADIT Trial. , 2018, Journal of the American College of Cardiology.

[5]  E. Fenwick,et al.  Cost-effectiveness of TYRX absorbable antibacterial envelope for prevention of cardiovascular implantable electronic device infection , 2018, Journal of medical economics.

[6]  C. Henrikson,et al.  Antibacterial Envelope Is Associated With Low Infection Rates After Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Device Replacement: Results of the Citadel and Centurion Studies. , 2017, JACC. Clinical electrophysiology.

[7]  B. Wilkoff,et al.  Worldwide Randomized Antibiotic EnveloPe Infection PrevenTion Trial (WRAP-IT). , 2016, American heart journal.

[8]  Christopher R. Ellis,et al.  Efficacy of a Bio‐Absorbable Antibacterial Envelope to Prevent Cardiac Implantable Electronic Device Infections in High‐Risk Subjects , 2015, Journal of cardiovascular electrophysiology.

[9]  S. Saba,et al.  Health and Economic Outcomes Associated with Use of an Antimicrobial Envelope as a Standard of Care for Cardiac Implantable Electronic Device Implantation , 2015, Journal of cardiovascular electrophysiology.

[10]  C. Henrikson,et al.  Increased Long‐Term Mortality in Patients with Cardiovascular Implantable Electronic Device Infections , 2015, Pacing and clinical electrophysiology : PACE.

[11]  Walid Saliba,et al.  Risk factors for 1-year mortality among patients with cardiac implantable electronic device infection undergoing transvenous lead extraction: the impact of the infection type and the presence of vegetation on survival. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[12]  H. Heidbuchel,et al.  Predictors of 30-day and 1-year mortality after transvenous lead extraction: a single-centre experience. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[13]  S. Mittal,et al.  Cardiac implantable electronic device infections: incidence, risk factors, and the effect of the AigisRx antibacterial envelope. , 2014, Heart rhythm.

[14]  L. Watkins,et al.  Rifampin inhibits Toll‐like receptor 4 signaling by targeting myeloid differentiation protein 2 and attenuates neuropathic pain , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  A. Zarzuelo,et al.  Minocycline: far beyond an antibiotic , 2013, British journal of pharmacology.

[16]  Christopher R. Ellis,et al.  Use of an Antibacterial Envelope is Associated with Reduced Cardiac Implantable Electronic Device Infections in High‐Risk Patients , 2013, Pacing and clinical electrophysiology : PACE.

[17]  M. Chung,et al.  Cardiovascular Implantable Electronic Device Replacement Infections and Prevention: Results from the REPLACE Registry , 2012, Pacing and clinical electrophysiology : PACE.

[18]  M. Sohail,et al.  Implantation Success and Infection in Cardiovascular Implantable Electronic Device Procedures Utilizing an Antibacterial Envelope , 2011, Pacing and clinical electrophysiology : PACE.

[19]  Walter R Wilson,et al.  Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. , 2010, Circulation.

[20]  J. Valle,et al.  Risk Factors for Mortality in Patients With Cardiac Device-Related Infection , 2009, Circulation. Arrhythmia and electrophysiology.

[21]  M H Samore,et al.  Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. , 2000, Circulation.